Re-evaluating the efficacy of beta-adrenergic agonists and antagonists in long QT-3 syndrome through computational modelling.

AIMS Long QT syndrome (LQTS) is a heterogeneous collection of inherited cardiac ion channelopathies characterized by a prolonged electrocardiogram QT interval and increased risk of sudden cardiac death. Beta-adrenergic blockers are the mainstay of treatment for LQTS. While their efficacy has been demonstrated in LQTS patients harbouring potassium channel mutations, studies of beta-blockers in subtype 3 (LQT3), which is caused by sodium channel mutations, have produced ambiguous results. In this modelling study, we explore the effects of beta-adrenergic drugs on the LQT3 phenotype. METHODS AND RESULTS In order to investigate the effects of beta-adrenergic activity and to identify sources of ambiguity in earlier studies, we developed a computational model incorporating the effects of beta-agonists and beta-blockers into an LQT3 mutant guinea pig ventricular myocyte model. Beta-activation suppressed two arrhythmogenic phenomena, transmural dispersion of repolarization and early after depolarizations, in a dose-dependent manner. However, the ability of beta-activation to prevent cardiac conduction block was pacing-rate-dependent. Low-dose beta-blockade by propranolol reversed the beneficial effects of beta-activation, while high dose (which has off-target sodium channel effects) decreased arrhythmia susceptibility. CONCLUSION These results demonstrate that beta-activation may be protective in LQT3 and help to reconcile seemingly conflicting results from different experimental models. They also highlight the need for well-controlled clinical investigations re-evaluating the use of beta-blockers in LQT3 patients.

[1]  M. Boutjdir,et al.  Role of subendocardial Purkinje network in triggering torsade de pointes arrhythmia in experimental long QT syndrome. , 2008, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[2]  Niels F. Otani,et al.  Dynamic Mechanism for Initiation of Ventricular Fibrillation In Vivo , 2008, Circulation.

[3]  A. Grace,et al.  Pharmacological separation of early afterdepolarizations from arrhythmogenic substrate in ΔKPQ Scn5a murine hearts modelling human long QT 3 syndrome , 2008, Acta physiologica.

[4]  K. Iijima,et al.  Antiarrhythmic vs. pro-arrhythmic effects depending on the intensity of adrenergic stimulation in a canine anthopleurin-A model of type-3 long QT syndrome. , 2008, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[5]  Ronit V. Oren,et al.  Progesterone Regulates Cardiac Repolarization Through a Nongenomic Pathway: An In Vitro Patch-Clamp and Computational Modeling Study , 2007, Circulation.

[6]  Guy Salama,et al.  Mouse models of long QT syndrome , 2007, The Journal of physiology.

[7]  M. Bouvier,et al.  Distinct Signaling Profiles of β1 and β2 Adrenergic Receptor Ligands toward Adenylyl Cyclase and Mitogen-Activated Protein Kinase Reveals the Pluridimensionality of Efficacy , 2006, Molecular Pharmacology.

[8]  Dirk Isbrandt,et al.  C-terminal HERG (LQT2) mutations disrupt IKr channel regulation through 14-3-3epsilon. , 2006, Human molecular genetics.

[9]  H. Tan,et al.  Cellular basis of sex disparities in human cardiac electrophysiology , 2006, Acta physiologica.

[10]  P J Noble,et al.  Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium–calcium overload , 2006, Heart.

[11]  M. Sanguinetti,et al.  hERG potassium channels and cardiac arrhythmia , 2006, Nature.

[12]  A. V. van Ginneken,et al.  Long‐QT syndrome‐related sodium channel mutations probed by the dynamic action potential clamp technique , 2006, The Journal of physiology.

[13]  W. Colledge,et al.  Paced Electrogram Fractionation Analysis of Arrhythmogenic Tendency in ΔKPQ Scn5a Mice , 2005, Journal of cardiovascular electrophysiology.

[14]  G. Tomaselli,et al.  Molecular basis of arrhythmias. , 2005, Circulation.

[15]  K. Sampson,et al.  Autonomic Control of Cardiac Action Potentials: Role of Potassium Channel Kinetics in Response to Sympathetic Stimulation , 2005, Circulation research.

[16]  S. Priori,et al.  Association of Long QT Syndrome Loci and Cardiac Events Among Patients Treated With β-Blockers , 2004 .

[17]  Y. Rudy.  From Genetics to Cellular Function Using Computational Biology , 2004, Annals of the New York Academy of Sciences.

[18]  Wouter-Jan Rappel,et al.  The role of M cells and the long QT syndrome in cardiac arrhythmias: simulation studies of reentrant excitations using a detailed electrophysiological model. , 2004, Chaos.

[19]  A. McCulloch,et al.  Modeling β-Adrenergic Control of Cardiac Myocyte Contractility in Silico* , 2003, Journal of Biological Chemistry.

[20]  S. Priori,et al.  Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. , 2003, Journal of the American College of Cardiology.

[21]  Y. Rudy,et al.  Ionic Current Basis of Electrocardiographic Waveforms: A Model Study , 2002, Circulation research.

[22]  Willem Flameng,et al.  Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome , 2001, Nature Medicine.

[23]  Y Rudy,et al.  Action potential and contractility changes in [Na(+)](i) overloaded cardiac myocytes: a simulation study. , 2000, Biophysical journal.

[24]  C. Antzelevitch,et al.  Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. , 2000, Journal of the American College of Cardiology.

[25]  S. Priori,et al.  Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. , 2000, Circulation.

[26]  J. Towbin,et al.  Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. , 1999, Circulation research.

[27]  Y. Rudy,et al.  Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia , 1999, Nature.

[28]  P. C. Viswanathan,et al.  Effects of IKr and IKs heterogeneity on action potential duration and its rate dependence: a simulation study. , 1999, Circulation.

[29]  Y Rudy,et al.  Ionic mechanisms of propagation in cardiac tissue. Roles of the sodium and L-type calcium currents during reduced excitability and decreased gap junction coupling. , 1997, Circulation research.

[30]  A. George,et al.  Pharmacological targeting of long QT mutant sodium channels. , 1997, The Journal of clinical investigation.

[31]  S. Priori,et al.  Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome. , 1996, Circulation research.

[32]  S. Priori,et al.  Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. , 1995, Human molecular genetics.

[33]  A. George,et al.  Molecular mechanism for an inherited cardiac arrhythmia , 1995, Nature.

[34]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[35]  Arthur J Moss,et al.  SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome , 1995, Cell.

[36]  E. Green,et al.  A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.

[37]  C. Luo,et al.  A dynamic model of the cardiac ventricular action potential. II. Afterdepolarizations, triggered activity, and potentiation. , 1994, Circulation research.

[38]  F. Abboud,et al.  Sympathetic-nerve activity during sleep in normal subjects. , 1993, The New England journal of medicine.

[39]  A. Moss,et al.  Left Cardiac Sympathetic Denervation in the Therapy of Congenital Long QT Syndrome: A Worldwide Report , 1991, Circulation.

[40]  A. K. Dawson,et al.  Electrophysiologic actions of high plasma concentrations of propranolol in human subjects. , 1983, Journal of the American College of Cardiology.

[41]  J. Oates,et al.  Suppression of Chronic Ventricular Arrhythmias with Propranolol , 1979, Circulation.

[42]  E. F. Luckstead,et al.  Effect of propranolol on the fast inward sodium current in frog atrial muscle. , 1973, The Journal of pharmacology and experimental therapeutics.

[43]  T. Jespersen,et al.  Antiarrhythmic effect of IKr activation in a cellular model of LQT3. , 2009, Heart rhythm.

[44]  Yoram Rudy,et al.  Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation. , 2007, American journal of physiology. Heart and circulatory physiology.

[45]  G. Breithardt,et al.  Life-threatening Arrhythmias Genotype-phenotype Correlation in the Long-qt Syndrome : Gene-specific Triggers for Genotype-phenotype Correlation in the Long-qt Syndrome Gene-specific Triggers for Life-threatening Arrhythmias , 2022 .